Daniel Blom, PhD

Daniel joined Cygnal Therapeutics from GlaxoSmithKline, where he most recently held positions as Director of Biochemistry in the Discovery Partnerships with Academia (DPAc) group and site head of the GSK Cambridge satellite site. He was responsible for leading preclinical R&D programs, which were focused on the development of both therapeutic monoclonal antibodies as well as small molecules.

Prior to working in DPAc, Daniel held a similar position as Director of Biochemistry in the Virtual Proof of Concept group at GlaxoSmithKline, where he was also responsible for leading the pre-clinical development of both therapeutic monoclonal antibodies and small molecules.

Before joining GSK, Daniel worked at Merck Research Laboratories. In his last role as a Director of Biologics, Daniel co-lead antibody development programs for the Cardiovascular Diseases and Neurosciences departments. Subsequently, Daniel was part of the atherosclerosis new targets team, where he focused on identifying new therapeutic targets by analysis of human genetics data and he led multiple lead discovery programs in the atherosclerosis department.

Daniel received his undergraduate degree in Chemistry and Master's degree with honors in Chemistry, specializing in Biochemistry from the University of Amsterdam. He completed his Ph.D. training at the University of Amsterdam as well in Biochemistry. He worked as a postdoctoral fellow in the Academic Medical Center in Amsterdam and subsequently trained as a postdoctoral fellow at Harvard Medical School.

Daniel Blom, PhD headshot

Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.